DelveInsight’s “Amyloidosis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Amyloidosis, historical and forecasted epidemiology as well as the Amyloidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

 

Key Takeaways from the Amyloidosis Market Research Report

• The increase in Amyloidosis Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Amyloidosis Market is anticipated to witness growth at a considerable CAGR.
• The leading Amyloidosis Companies working in the market include Attralus Inc., Novotech Pty Limited, Criterium Inc., Amgen, Millennium Pharmaceuticals Inc., Johnson & Johnson Pharmaceuticals, Intellia Therapeutiscs, Regeneron Pharmaceuticals, Akcea Therapeutics, GlaxoSmithKline, United BioSource LLC, and others
• Promising Amyloidosis Therapies in the various stages of development include AT-02, Carfilzomib, Dexamethasone, VELCADE, NTLA-2001, GSK2398852, Eplontersen, and others.
• April 2024:- Attralus Inc.- A Three-part, Phase 1, Single-ascending, and Multiple-ascending Dose Escalation Study in Healthy Volunteers and Subjects With Systemic Amyloidosis to Assess the Safety, Tolerability, and Pharmacokinetics of AT-02. This is a multicenter, international, three-part, Phase 1 study designed to evaluate the safety, tolerability, and PK of rising single doses of AT-02 in healthy volunteers and in subjects with systemic amyloidosis and to assess the safety, tolerability, and PK of multiple doses of AT-02 in subjects with systemic amyloidosis.
• April 2024:- Intellia Therapeutics- MAGNITUDE: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM). To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.
• April 2024:- Akcea Therapeutics- A Prospective, Non-interventional, Long-term, Multinational Cohort Safety Study of Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (hATTR-PN). This is a prospective, non-interventional, Long-term, multinational cohort safety study of patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (hATTR-PN). The overarching goal of this study is to further characterize the long-term safety of TEGSEDI (inotersen) in patients with hATTR-PN under real-world conditions.

 

Discover which therapies are expected to grab the Amyloidosis Market Share @ Amyloidosis Market Outlook

 

Amyloidosis Overview

Amyloidosis is a group of diseases characterized by the abnormal buildup of a protein called amyloid in various organs and tissues of the body. Amyloid is a protein that normally circulates in the blood, but in amyloidosis, it becomes misfolded and clumps together to form insoluble fibers. These fibers can accumulate in different organs such as the heart, kidneys, liver, spleen, nervous system, and digestive tract, interfering with their normal function and leading to organ damage and failure.

 

Amyloidosis Epidemiology Insights

The epidemiology section of Amyloidosis offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

 

Download the report to understand which factors are driving Amyloidosis Epidemiology trends @ Amyloidosis Epidemiological Insights

 

Amyloidosis Drugs Market

The Amyloidosis Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Amyloidosis signaling in Amyloidosis are likely to uncover new therapeutic targets and further expand treatment options for patients.

 

Amyloidosis Treatment Market Landscape

The Amyloidosis treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Amyloidosis has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

 

To learn more about Amyloidosis treatment guidelines, visit @ Amyloidosis Treatment Market Landscape

 

Amyloidosis Market Outlook

The report’s outlook on the Amyloidosis market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Amyloidosis therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Amyloidosis drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Amyloidosis market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

 

Amyloidosis Drugs Uptake

The drug chapter of the Amyloidosis report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Amyloidosis.

 

Major Amyloidosis Companies

Several Amyloidosis Companies working in the market include Attralus Inc., Novotech Pty Limited, Criterium Inc., Amgen, Millennium Pharmaceuticals Inc., Johnson & Johnson Pharmaceuticals, Intellia Therapeutics, Regeneron Pharmaceuticals, Akcea Therapeutics, GlaxoSmithKline, United BioSource LLC, and others

 

Learn more about the FDA-approved drugs for Amyloidosis @ Drugs for Amyloidosis Treatment

 

Scope of the Amyloidosis Market Report

• Coverage- 7MM
• Amyloidosis Companies- Attralus Inc., Novotech Pty Limited, Criterium Inc., Amgen, Millennium Pharmaceuticals Inc., Johnson & Johnson Pharmaceuticals, Intellia Therapeutiscs, Regeneron Pharmaceuticals, Akcea Therapeutics, GlaxoSmithKline, United BioSource LLC, and others
• Amyloidosis Therapies- AT-02, Carfilzomib, Dexamethasone, VELCADE, NTLA-2001, GSK2398852, Eplontersen, and others.
• Amyloidosis Market Dynamics: Amyloidosis Market Drivers and Barriers
• Amyloidosis Market Access and Reimbursement, Unmet Needs and Future Perspectives

 

Discover more about Amyloidosis Drugs in development @ Amyloidosis Clinical Trials Assessment

 

Table of Content

1. Key Insights

2. Executive Summary

3. Competitive Intelligence Analysis

4. Amyloidosis: Market Overview at a Glance

5. Amyloidosis: Disease Background and Overview

6. Patient Journey

7. Amyloidosis Epidemiology and Patient Population

8. Amyloidosis Treatment Algorithm, Current Treatment, and Medical Practices

9. Amyloidosis Unmet Needs

10. Key Endpoints of Amyloidosis Treatment

11. Amyloidosis Marketed Products

12. Amyloidosis Emerging Therapies

13. Amyloidosis: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Amyloidosis

17. KOL Views

18. Amyloidosis Market Drivers

19. Amyloidosis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/